We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
Read MoreHide Full Article
Novavax (NVAX - Free Report) closed at $8.52 in the latest trading session, marking a -2.07% move from the prior day. This change lagged the S&P 500's 0.23% gain on the day. Elsewhere, the Dow saw an upswing of 0.34%, while the tech-heavy Nasdaq appreciated by 0.8%.
The vaccine maker's stock has climbed by 1.52% in the past month, falling short of the Medical sector's gain of 5.57% and the S&P 500's gain of 3.57%.
Analysts and investors alike will be keeping a close eye on the performance of Novavax in its upcoming earnings disclosure. In that report, analysts expect Novavax to post earnings of -$0.81 per share. This would mark a year-over-year decline of 6.58%. In the meantime, our current consensus estimate forecasts the revenue to be $40.94 million, indicating a 51.55% decline compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $2.26 per share and revenue of $1.05 billion, which would represent changes of +283.74% and +54.5%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Novavax. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 15.67% decrease. As of now, Novavax holds a Zacks Rank of #3 (Hold).
With respect to valuation, Novavax is currently being traded at a Forward P/E ratio of 3.85. For comparison, its industry has an average Forward P/E of 19.33, which means Novavax is trading at a discount to the group.
We can also see that NVAX currently has a PEG ratio of 0.13. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.62 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 89, placing it within the top 37% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
Novavax (NVAX - Free Report) closed at $8.52 in the latest trading session, marking a -2.07% move from the prior day. This change lagged the S&P 500's 0.23% gain on the day. Elsewhere, the Dow saw an upswing of 0.34%, while the tech-heavy Nasdaq appreciated by 0.8%.
The vaccine maker's stock has climbed by 1.52% in the past month, falling short of the Medical sector's gain of 5.57% and the S&P 500's gain of 3.57%.
Analysts and investors alike will be keeping a close eye on the performance of Novavax in its upcoming earnings disclosure. In that report, analysts expect Novavax to post earnings of -$0.81 per share. This would mark a year-over-year decline of 6.58%. In the meantime, our current consensus estimate forecasts the revenue to be $40.94 million, indicating a 51.55% decline compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $2.26 per share and revenue of $1.05 billion, which would represent changes of +283.74% and +54.5%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Novavax. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 15.67% decrease. As of now, Novavax holds a Zacks Rank of #3 (Hold).
With respect to valuation, Novavax is currently being traded at a Forward P/E ratio of 3.85. For comparison, its industry has an average Forward P/E of 19.33, which means Novavax is trading at a discount to the group.
We can also see that NVAX currently has a PEG ratio of 0.13. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.62 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 89, placing it within the top 37% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.